{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:38:31Z","timestamp":1777012711068,"version":"3.51.4"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic inducible urticaria (CIndU) is a group of diseases characterized by recurrent wheals and\/or angioedema induced by specific triggers. Research into its underlying mechanisms remains underdeveloped, historically lagging behind that of chronic spontaneous urticaria (CSU). The profound heterogeneity across CIndU subtypes presents a central challenge, translating into limited and variable efficacy of conventional therapies, including second-generation H1-antihistamines and omalizumab, highlighting the inadequacy of a uniform management strategy. Encouragingly, the clinical development of novel targeted agents, notably anti-KIT biologics and Bruton\u2019s tyrosine kinase (BTK) inhibitors, now offers new promise. Concurrently, the refinement of disease-specific assessment tools and the exploration of biomarkers are facilitating a more personalized approach. This review summarizes recent advances and persistent challenges in CIndU management, advocating for a concerted effort to deepen mechanistic understanding, validate predictive biomarkers, and integrate patient stratification into future clinical trials, thereby paving the way for precision medicine in this field.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1747542","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:43:29Z","timestamp":1777009409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancements and challenges in the management of chronic inducible urticaria"],"prefix":"10.3389","volume":"17","author":[{"given":"Menghao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.019","article-title":"Chronic spontaneous urticaria and chronic inducible urticaria","volume":"156","author":"Lee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901851","article-title":"Evidence for histamine release in chronic inducible urticaria \u2013 a systematic review","volume":"13","author":"Kulthanan","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/all.16250","article-title":"An algorithm for the diagnosis and treatment of chronic inducible urticaria, 2024 update","volume":"79","author":"Maurer","year":"2024","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.12338","article-title":"Chronic urticaria in Chinese population: A hospital-based multicenter epidemiological study","volume":"69","author":"Zhong","year":"2014","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100610","article-title":"Expert consensus on the use of omalizumab in chronic urticaria in China","volume":"14","author":"Zhao","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1584771","article-title":"Chronic inducible urticaria \u2013 having more than one is common and clinically relevant","volume":"16","author":"Lebedkina","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13841","article-title":"Cold urticaria: A 20\u2010year follow\u2010up study","volume":"30","author":"Jain","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12974-025-03397-4","article-title":"Beyond the itch: The complex interplay of immune, neurological, and psychological factors in chronic urticaria","volume":"22","author":"Yang","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society*","volume":"184","author":"Gon\u00e7alo","year":"2021","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01160-y","article-title":"New insights into chronic inducible urticaria","volume":"24","author":"Mu\u00f1oz","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaip.2023.11.029","article-title":"Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights","volume":"12","author":"Kovalkova","year":"2024","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1487831","article-title":"Key differences between chronic inducible and spontaneous urticaria","volume":"5","author":"Bizjak","year":"2024","journal-title":"Front Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40257-022-00728-6","article-title":"Cholinergic urticaria: Subtype classification and clinical approach","volume":"24","author":"Fukunaga","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19637","article-title":"A comparative analysis of chronic inducible urticaria in 423 patients: Clinical and laboratory features and comorbid conditions","volume":"38","author":"Ornek Ozdemir","year":"2024","journal-title":"Acad Dermatol Venereol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002172","article-title":"Epidemiology of urticaria in China: A population-based study","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (engl)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000536579","article-title":"Unveiling treatment response predictors in predominant subtypes of chronic inducible urticaria","volume":"185","author":"Ornek Ozdemir","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias - the EAACI\/GA2 LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.05.011","article-title":"Evaluation of guideline line-care approach to the treatment of chronic inducible urticaria","volume":"12","author":"S\u00e1nchez","year":"2024","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jaad.2016.06.017","article-title":"Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort","volume":"75","author":"Deza","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00403-024-03447-6","article-title":"Decoding the variability in clinical and laboratory profiles of chronic inducible urticaria vs. Chronic spontaneous urticaria - a retrospective study from a tertiary care center","volume":"316","author":"Kumaran","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15928","article-title":"Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta\u2010analysis","volume":"35","author":"He","year":"2022","journal-title":"Dermatologic Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2024.03.003","article-title":"Chronic inducible urticaria","volume":"44","author":"Ritzel","year":"2024","journal-title":"Immunol Allergy Clinics North America"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.01.031","article-title":"Chronic inducible urticaria: A systematic review of treatment options","volume":"141","author":"Dressler","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100460","article-title":"Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results","volume":"13","author":"Maurer","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/all.15585","article-title":"Anti\u2010KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst\u2010Molawi","year":"2023","journal-title":"Allergy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/all.15262","article-title":"Anti\u2010KIT monoclonal antibody CDX\u20100159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.anai.2024.10.006","article-title":"Positive efficacy and favorable safety of barzolvolimab in chronic inducible urticaria: Phase II trial results","volume":"133","author":"Maurer","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12227","article-title":"Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of Fc\u03f5R1 expression level and omalizumab clinical response","volume":"13","author":"Gimeno","year":"2023","journal-title":"Clin Trans All"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13102","article-title":"Development and validation of the cholinergic urticaria quality\u2010of\u2010life questionnaire (CholU\u2010QoL)","volume":"48","author":"Ruft","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.jaip.2025.04.012","article-title":"Validation of the urticaria activity score for cold urticaria","volume":"13","author":"Grekowitz","year":"2025","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.jaip.2025.04.047","article-title":"Development and validation of a disease severity index for patients with cold urticaria","volume":"13","author":"Altunergil","year":"2025","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_523_2024","article-title":"Outcome measures in chronic urticaria: A comprehensive review","volume":"91","author":"Shah","year":"2025","journal-title":"IJDVL"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411328","article-title":"Biomarkers for monitoring treatment response of omalizumab in patients with chronic urticaria","volume":"24","author":"Pedersen","year":"2023","journal-title":"IJMS"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e211","article-title":"Omalizumab on chronic spontaneous urticaria and chronic inducible urticaria: A real-world study of efficacy and predictors of treatment outcome","volume":"37","author":"Jeong","year":"2022","journal-title":"J Korean Med Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2025.17.5.547","article-title":"Cold urticaria: From wheals to anaphylaxis","volume":"17","author":"Bizjak","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995596","article-title":"IgE receptor responsiveness of basophils in chronic inducible urticaria","volume":"13","author":"Mizuno","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/ijd.17102","article-title":"Shedding light on dermographism: A narrative review","volume":"63","author":"Zhang","year":"2024","journal-title":"Int J Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-017-0418-6","article-title":"Cholinergic urticaria: Epidemiology, physiopathology, new categorization, and management","volume":"28","author":"Fukunaga","year":"2018","journal-title":"Clin Auton Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14493","article-title":"Pathogenesis of solar urticaria: Classic perspectives and emerging concepts","volume":"31","author":"McSweeney","year":"2022","journal-title":"Exp Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"382","DOI":"10.12932\/AP-130825-2133","article-title":"Pathophysiological insights into delayed pressure urticaria: A comprehensive review","volume":"43","author":"Kulthanan","year":"2025","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198110293051808","article-title":"Idiopathic cold urticaria: In vitro demonstration of histamine release upon challenge of skin biopsies","volume":"305","author":"Kaplan","year":"1981","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1016\/j.jaip.2023.09.042","article-title":"The pathogenesis of primary acquired cold urticaria","volume":"11","author":"Kaplan","year":"2023","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1038\/ncomms7866","article-title":"Structural basis for binding of human IgG1 to its high-affinity human receptor Fc\u03b3RI","volume":"6","author":"Kiyoshi","year":"2015","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2003.00010.x","article-title":"Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test","volume":"12","author":"Caproni","year":"2003","journal-title":"Exp Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.02.283","article-title":"Management of chronic inducible urticaria according to the guidelines: A prospective controlled study","volume":"87","author":"Kocat\u00fcrk","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100501","article-title":"Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both","volume":"14","author":"Chen","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19425","article-title":"Omalizumab for the treatment of chronic inducible urticaria in 80 patients","volume":"184","author":"Exposito-Serrano","year":"2021","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/all.16334","article-title":"Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study","volume":"80","author":"Soegiharto","year":"2025","journal-title":"Allergy"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.05.016","article-title":"Symptomatic dermographism: A systematic review of treatment options","volume":"8","author":"Kulthanan","year":"2020","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.31744\/einstein_journal\/2020AO5175","article-title":"Chronic inducible urticaria: Confirmation through challenge tests and response to treatment","volume":"18","author":"Pereira","year":"2020","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109198","article-title":"An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria","volume":"112","author":"Ayse Ornek","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and safety of omalizumab (xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: A randomized mixed double-blind and open-label placebo-controlled clinical trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14010","article-title":"Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature","volume":"33","author":"Ghazanfar","year":"2020","journal-title":"Dermatologic Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.jaip.2020.03.004","article-title":"Delayed pressure urticaria: A systematic review of treatment options","volume":"8","author":"Kulthanan","year":"2020","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13979","article-title":"Real-life treatment of patients with cholinergic urticaria in German-speaking countries","volume":"17","author":"Mellerowicz","year":"2019","journal-title":"J Deutsche Derma Gesell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1159\/000514757","article-title":"Clinical characteristics, management, and natural history of chronic inducible urticaria in a pediatric cohort","volume":"182","author":"Miles","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165736","article-title":"Efficacy of therapies for solar urticaria: A systematic review and meta-analysis","volume":"14","author":"Engler Markowitz","year":"2025","journal-title":"JCM"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094658","article-title":"Altered sweat composition due to changes in tight junction expression of sweat glands in cholinergic urticaria patients","volume":"25","author":"Daci","year":"2024","journal-title":"IJMS"},{"key":"B64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.alit.2020.05.006","article-title":"Direct and indirect action modes of acetylcholine in cholinergic urticaria","volume":"70","author":"Tokura","year":"2021","journal-title":"Allergology Int"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955161","article-title":"Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0649","article-title":"Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: A systematic review of the literature","volume":"31","author":"Iriarte Sot\u00e9s","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04185.x","article-title":"Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses","volume":"26","author":"Zuberbier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2023.15.4.496","article-title":"Efficacy of second-line treatments in chronic urticaria refractory to standard dose antihistamines","volume":"15","author":"Kim","year":"2023","journal-title":"Allergy Asthma Immunol Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2150","article-title":"Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria","volume":"96","author":"Abajian","year":"2016","journal-title":"Acta Derm Venerol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/all.14674","article-title":"Cold urticaria \u2013 What we know and what we do not know","volume":"76","author":"Maltseva","year":"2021","journal-title":"Allergy"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.jaci.2016.05.026","article-title":"Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria","volume":"138","author":"Koch","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15386","article-title":"Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study","volume":"35","author":"Qian","year":"2022","journal-title":"Dermatologic Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.23822\/EurAnnACI.1764-1489.103","article-title":"Clinical experience of a chronic urticaria referral university center","volume":"52","author":"Andrade Coelho Dias","year":"2020","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: Evaluation of 154 patients","volume":"175","author":"Ghazanfar","year":"2016","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1159\/000529250","article-title":"Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria","volume":"184","author":"Yang","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Metz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13960","article-title":"Real-life experience in the treatment of solar urticaria: Retrospective cohort study","volume":"44","author":"Snast","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15346","article-title":"A localized salt-dependent aquagenic urticaria successfully treated with omalizumab","volume":"47","author":"Carra","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02268.x","article-title":"Effective treatment of refractory severe heat urticaria with omalizumab","volume":"65","author":"Bullerkotte","year":"2010","journal-title":"Allergy"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13838","article-title":"Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response","volume":"51","author":"Yu","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.25576","article-title":"Solar urticaria: An ambispective study in a long-term follow-up cohort with emphasis on therapeutic predictors and outcomes","volume":"104","author":"Pesqu\u00e9","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16407","article-title":"Treatment of severe heat urticaria with omalizumab \u2013 report of a case and review of the literature","volume":"34","author":"Bonnekoh","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17385","article-title":"Effectiveness of omalizumab in patients with chronic inducible urticaria: Real-life experience from two UCARE centres","volume":"35","author":"Can","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08109.x","article-title":"Cold urticaria: Tolerance induction with cold baths","volume":"157","author":"Von Mackensen","year":"2007","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_727_2023","article-title":"Cold urticaria in tropics: A clinico-epidemiological study from north India","volume":"91","author":"Mehta","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.06.004","article-title":"Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis","volume":"156","author":"Chu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06757.x","article-title":"Cold urticaria; disease course and outcome - an investigation of 85 patients before and after therapy","volume":"153","author":"Buss","year":"2005","journal-title":"Br J Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14820","article-title":"Patients with chronic cold urticaria may benefit from doxycycline therapy","volume":"176","author":"Gorczyza","year":"2017","journal-title":"Br J Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/09546634.2017.1329505","article-title":"Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: A review of published evidence","volume":"29","author":"Holm","year":"2018","journal-title":"J Dermatol Treat"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2011.07749.x","article-title":"Delayed pressure urticaria \u2013 dapsone heading for first-line therapy","volume":"9","author":"Grundmann","year":"2011","journal-title":"J Deutsche Derma Gesell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12266","article-title":"Delayed pressure urticaria: Response to treatment with sulfasalazine in a case series of seventeen patients: response of DPU to sulfasalazine","volume":"28","author":"Swerlick","year":"2015","journal-title":"Dermatologic Ther"},{"key":"B96","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-157-8-201210160-00023","article-title":"Efficiency of interleukin-1 blockade in refractory delayed-pressure urticaria","volume":"157","author":"Lenormand","year":"2012","journal-title":"Ann Intern Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12851","article-title":"Delayed pressure urticaria treated with the selective serotonin reuptake inhibitor escitalopram","volume":"41","author":"Eskeland","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07533.x","article-title":"Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: A randomized, double-blind, placebo-controlled study: desloratadine + montelukast for DPU","volume":"155","author":"Nettis","year":"2006","journal-title":"Br J Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/all.70210","article-title":"The international guideline for the definition, classification, diagnosis and management of urticaria","author":"Zuberbier","year":"2026","journal-title":"Allergy"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaip.2019.12.006","article-title":"Long-term combinations and updosing of second-generation H1-antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: A multicenter real-life pilot study","volume":"8","author":"Zhang","year":"2020","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usae333","article-title":"Delayed pressure urticaria associated with altitude chamber training responsive to cyclosporine and omalizumab","volume":"189","author":"Alix","year":"2024","journal-title":"Mil Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2014.07.023","article-title":"Severe and refractory solar urticaria treated with intravenous immunoglobulins: A phase II multicenter study","volume":"71","author":"Aubin","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","article-title":"Chronic urticaria: Unmet needs, emerging drugs, and new perspectives on personalised treatment","volume":"404","author":"Zuberbier","year":"2024","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(79)92664-3","article-title":"Cold urticaria treated by induction of tolerance","volume":"314","author":"Kobza Black","year":"1979","journal-title":"Lancet"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1975.tb03057.x","article-title":"Localized heat urticaria treated by inducing tolerance to heat","volume":"92","author":"Leigh","year":"1975","journal-title":"Br J Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12447","article-title":"Successful treatment of solar urticaria with UVA1 hardening in three patients","volume":"35","author":"Lyons","year":"2019","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.05.020","article-title":"The future of targeted therapy in chronic spontaneous urticaria","volume":"133","author":"Min","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111499","article-title":"Therapies for chronic spontaneous urticaria: Present and future developments","volume":"17","author":"Asero","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.052","article-title":"Successful ligelizumab treatment of severe refractory solar urticaria","volume":"11","author":"Hershkovitz","year":"2023","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2182620","article-title":"Efficacity of dupilumab in severe idiopathic cold urticaria: A case report","volume":"34","author":"Marchal","year":"2023","journal-title":"J Dermatol Treat"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15025","article-title":"Treatment of refractory solar urticaria: could dupilumab fill the current gap","volume":"21","author":"Navarro\u2010Trivi\u00f1o","year":"2023","journal-title":"J Deutsche Derma Gesell"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14081","article-title":"Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment","volume":"45","author":"Ferrucci","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S343462","article-title":"Cholinergic urticaria, an effective and safe \u201coff label\u201d use of dupilumab: A case report with literature review","volume":"15","author":"Sirufo","year":"2022","journal-title":"CCID"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2277385","article-title":"Inhibition of KIT for chronic urticaria: A status update on drugs in early clinical development","volume":"32","author":"Wedi","year":"2023","journal-title":"Expert Opin Invest Drugs"},{"key":"B116","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.anai.2025.08.115","article-title":"Sustained efficacy and safety of barzolvolimab in cindu","volume":"135","author":"Metz","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.07.019","article-title":"Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates","volume":"156","author":"Lee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17707","article-title":"Type 2 Inflammation and Its Role in Dermatologic Diseases","volume":"64","author":"Chovatiya","year":"2025","journal-title":"Int J Dermatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01231-y","article-title":"Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels","volume":"14","author":"Maurer","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.05.004","article-title":"Dupilumab for chronic spontaneous urticaria\u2014marvelous or meek","volume":"154","author":"Mathur","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling\u2014a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances","volume":"78","author":"Kaplan","year":"2023","journal-title":"Allergy"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2510892","article-title":"Evaluating remibrutinib in the treatment of chronic spontaneous urticaria","volume":"17","author":"Bo\u017cek","year":"2025","journal-title":"Immunotherapy"},{"key":"B126","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/all.14213","article-title":"The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: Expression and function","volume":"75","author":"Wedi","year":"2020","journal-title":"Allergy"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgad056","article-title":"Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2","volume":"75","author":"Zhang","year":"2023","journal-title":"J Pharm Pharmacol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein\u2013coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"K\u00fchn","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/pde.70093","article-title":"Resolution of refractory cholinergic urticaria in a child treated with dupilumab","volume":"43","author":"Meara","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/all.14950","article-title":"Effects of pregnancy on chronic urticaria: Results of the PREG\u2010CU UCARE study","volume":"76","author":"Kocat\u00fcrk","year":"2021","journal-title":"Allergy"},{"key":"B135","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.reprotox.2008.05.053","article-title":"The safety of cetirizine during pregnancy","volume":"26","author":"Weber-Schoendorfer","year":"2008","journal-title":"Reprod Toxicol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831090-00006","article-title":"Risk of hypospadias in offspring of women using loratadine during pregnancy: A systematic review and meta-analysis","volume":"31","author":"Schwarz","year":"2008","journal-title":"Drug Saf"},{"key":"B137","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The xolair pregnancy registry (EXPECT): The safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2500\/aap.2023.44.220093","article-title":"Current and future management of chronic spontaneous urticaria and chronic inducible urticaria","volume":"44","author":"Do","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae038","article-title":"Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): Results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial","volume":"190","author":"Grekowitz","year":"2024","journal-title":"Br J Dermatol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.07.008","article-title":"Clinical Evaluation and Outcome Measures of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria","volume":"13","author":"Weller","year":"2025","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/all.15310","article-title":"Development of the cold urticaria activity score","volume":"77","author":"Ahsan","year":"2022","journal-title":"Allergy"},{"key":"B144","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaip.2024.10.011","article-title":"Validation of the cholinergic urticaria activity score (CholUAS)","volume":"13","author":"Schnarkowski","year":"2025","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.10.002","article-title":"Validation of the symptomatic dermographism quality of life questionnaire (SD-QoL)","volume":"14","author":"Mu\u00f1oz","year":"2025","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70038","article-title":"Development of the symptomatic dermographism quality of life questionnaire","volume":"15","author":"Mu\u00f1oz","year":"2025","journal-title":"Clin Trans All"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the urticaria control test: A patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100218","article-title":"Automatic urticaria activity score: Deep learning\u2013based automatic hive counting for urticaria severity assessment","volume":"4","author":"Mac Carthy","year":"2024","journal-title":"JID Innov"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jaip.2024.03.050","article-title":"Patient-reported outcome measures in atopic dermatitis and chronic urticaria are underused in clinical practice","volume":"12","author":"Cherrez-Ojeda","year":"2024","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/all.16371","article-title":"Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE\u00ae mobile health study","volume":"80","author":"Sousa-Pinto","year":"2025","journal-title":"Allergy"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12328","article-title":"CRUSE\u00ae - an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria","volume":"14","author":"Neisinger","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000636","article-title":"Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria","volume":"20","author":"Baiardini","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.05.051","article-title":"Prognostic calculator of the clinical response to antihistamines in chronic urticaria: external validation","volume":"13","author":"S\u00e1nchez","year":"2025","journal-title":"J Allergy Clin Immunology: In Pract"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1684\/ejd.2024.4600","article-title":"Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review","volume":"34","author":"Gimenez-Arnau","year":"2024","journal-title":"Eur J Dermatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.43568","article-title":"The predictive value of serum total IgE for antihistamine treatment outcomes in Chinese patients with chronic spontaneous urticaria","volume":"105","author":"Li","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12117","article-title":"IgE and high\u2010affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance","volume":"12","author":"Gim\u00e9nez\u2010Arnau","year":"2022","journal-title":"Clin Trans All"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1112917","article-title":"Self-reactive IgE and anti-IgE therapy in autoimmune diseases","volume":"14","author":"Olewicz-Gawlik","year":"2023","journal-title":"Front Pharmacol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154453","article-title":"Monoclonal antibodies in treating chronic spontaneous urticaria: new drugs for an old disease","volume":"11","author":"Manti","year":"2022","journal-title":"JCM"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1747542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:43:31Z","timestamp":1777009411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1747542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":160,"alternative-id":["10.3389\/fimmu.2026.1747542"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1747542","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1747542"}}